Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

In mice, a common gut antibody kept colorectal cancer in check

☕ Includes a question for the family ↓

Colorectal cancerPart of a story we are following · 6 articles · See every update
Broccoli heads growing among large leafy plants in an outdoor vegetable garden.
Broccoli heads growing among large leafy plants in an outdoor vegetable garden.Photo: Alabama Extension / Wikimedia Commons, CC0

Here is a quiet bit of news about your gut. Scientists found that an antibody your body makes every day may help keep the cells lining your colon from growing too fast. That matters for colorectal cancer, but so far this was shown only in mice, and it has not been tested in people.

In a lab study in mice published in Nature, mice without the antibody IgA were more likely to develop several kinds of colorectal cancer, and giving IgA by mouth protected them from tumors.

How the study worked

Researchers used genetically and environmentally controlled mice, plus a simple lab dish system of colon cells, to test what happens when IgA is missing. The work was published on November 11, 2026 in Nature. Mice and lab cells are not people, so the results show how the biology works, not what would happen in a human body.

What is IgA?

IgA is the most abundant antibody made by mammals. Most antibodies float in your blood. IgA works at the surface of your body’s linings, including your intestines. It is constantly released into the gut, where it attaches to the microbes that live there and helps manage how they settle in and behave.

IgA deficiency is common in people, but it is hard to study. The causes are complex and often come with other health conditions. That is why the researchers used carefully controlled mice.

What they found

The team tested several different ways of removing IgA from mice. In every case, the mice were more likely to develop several kinds of colorectal cancer that arise on their own.

Without IgA, the cells lining the colon reacted strongly to the bacteria in the gut. They switched on defenses against bacteria and sped up their cycle of dividing. Faster dividing means more chances for things to go wrong.

When the mice were given IgA by mouth, the cells slowed back down to a steady pace, and the mice were protected from tumors. Interestingly, this worked because of the shape and structure of the antibody, not because it recognized any particular microbe.

In a simplified dish of colon cells, IgA directly slowed their growth. The scientists then searched for how. They found a protein on the surface of colon cells called DMBT1 that IgA attaches to. Without DMBT1, IgA could not slow the cells down.

The last test tied it together. In mice that had no IgA, the team removed the part of DMBT1 that sits through the cell membrane and sends signals inside the cell. That alone reversed both the extra cell growth and the higher tumor risk.

In plain words: IgA and DMBT1 work as a pair, like a thermostat for the colon lining. They keep the growth of new colon cells at a healthy pace, even as gut bacteria push on them.

What you can do today

This finding does not change any medical advice yet, and there is no IgA treatment for people to try. The most useful step is the one that already exists: check when you should start colorectal cancer screening. Search for colorectal cancer screening on the CDC website, and ask your pharmacy or clinic what options are covered under your insurance or Medicare.

For clinicians and researchers

Design: Preclinical study in genetically and environmentally controlled mice with various models of IgA deficiency and several models of endogenous colorectal cancer, plus a reductionist epithelial culture system, co-immunoprecipitation mass spectrometry and targeted CRISPR screening.

Main result: Various models of IgA deficiency resulted in increased susceptibility to several models of endogenous colorectal cancer. Oral IgA reduced steady-state proliferation and protected mice from tumours, an effect dependent on antibody structure rather than binding specificity.

Main limitation: Mouse and culture-system data; findings have not been tested in humans, and the abstract notes that human IgA deficiency is difficult to study because of its complex aetiology and comorbidities.

Open question: Whether the IgA-DMBT1 pathway restrains epithelial proliferation and colorectal tumour risk in humans, including people with IgA deficiency, remains to be tested.

Talk about it at home

In this study, scientists worked with mice and found that a helper the body makes, called IgA, sits along the lining of the gut and teams up with a protein on the surface of colon cells. Together they keep new cells from dividing too fast, a bit like a dimmer switch that stops the lights from getting too bright. To check it, the scientists took away the protein partner and saw that the helper stopped working, which showed the two really belong together.

Find out together how often the lining of your belly renews itself, and why a body that is always making new cells needs something to keep the pace steady. See who at the table can find the most surprising fact.

Try it at home

Also cited: CDC

Keep exploring

Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. In mice, a common gut antibody kept colorectal cancer in check. Mongevity. Published November 21, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/gut-antibody-iga-colorectal-cancer-mice/
Vancouver
Mongevity Desk. In mice, a common gut antibody kept colorectal cancer in check [Internet]. Mongevity; 2026 Nov 21 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/gut-antibody-iga-colorectal-cancer-mice/
APA
Mongevity Desk. (2026, November 21). In mice, a common gut antibody kept colorectal cancer in check. Mongevity. https://mongevity.science/cancer/2026/11/gut-antibody-iga-colorectal-cancer-mice/
For your website
<a href="https://mongevity.science/cancer/2026/11/gut-antibody-iga-colorectal-cancer-mice/">In mice, a common gut antibody kept colorectal cancer in check</a>

Free to share or quote with credit and a link.

Questions and answers

What is IgA?
IgA is the most abundant antibody made by mammals. It is constantly released into the gut, where it attaches to microbes and helps manage how they live there.
Does this mean IgA can prevent colorectal cancer in people?
No. The work was done in mice and lab-grown cells. It has not been tested in people, so it shows how the biology works, not a treatment.
What is DMBT1?
DMBT1 is a protein on the surface of colon cells. IgA attaches to it, and this link is needed for IgA to slow cell growth.
Should I change my colorectal cancer screening because of this?
No. Current screening advice stays the same. Ask your clinic which test and starting age fit you.

Sources

  1. Nature: Suppression of epithelial proliferation and tumorigenesis by IgA (PMID 43015465 · DOI 10.1038/s41586-026-11264-2) · 2026-11-21

More on this story

Report an error